Silence Therapeutics (NASDAQ:SLN) Shares Up 3.2%

Silence Therapeutics plc (NASDAQ:SLN)’s share price shot up 3.2% on Tuesday . The company traded as high as $21.33 and last traded at $21.33. 9,683 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 238,158 shares. The stock had previously closed at $20.66.

Analyst Ratings Changes

A number of research firms recently weighed in on SLN. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. BMO Capital Markets began coverage on shares of Silence Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price objective on the stock. Morgan Stanley increased their price objective on shares of Silence Therapeutics from $29.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, March 14th. Finally, Chardan Capital increased their price objective on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th.

Silence Therapeutics Stock Performance

The stock’s 50-day moving average price is $23.00 and its 200 day moving average price is $16.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 4.56.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). The company had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. Sell-side analysts anticipate that Silence Therapeutics plc will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLN. Goldman Sachs Group Inc. boosted its stake in shares of Silence Therapeutics by 27.1% during the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock valued at $18,350,000 after purchasing an additional 205,815 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Silence Therapeutics in the second quarter valued at approximately $136,000. UBS Group AG boosted its stake in Silence Therapeutics by 4.8% in the fourth quarter. UBS Group AG now owns 69,006 shares of the company’s stock valued at $1,052,000 after acquiring an additional 3,191 shares in the last quarter. Morgan Stanley lifted its stake in shares of Silence Therapeutics by 36.0% during the fourth quarter. Morgan Stanley now owns 210,973 shares of the company’s stock worth $3,217,000 after buying an additional 55,814 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Silence Therapeutics by 19.8% during the fourth quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock worth $266,000 after buying an additional 2,879 shares during the period. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.